Nontuberculous Mycobacteria: Clinical Importance and Relevance to Bacille Calmette-Guérin Vaccination

Valadas, Emilia
August 2004
Clinical Infectious Diseases;8/15/2004, Vol. 39 Issue 4, p457
Academic Journal
The article focuses on nontuberculous mycobacteria (NTM) and its clinical importance and relevance to bacille calmette-guérin (BCG) vaccination. NTM have been recognized to cause human disease since the 1950s, but it was only later, when the AIDS pandemic unfolded, that a more widespread interest in these bacteria started to develop. Yet another important aspect of NTM infection is the role that BCG vaccination may have. There is some evidence that prior exposure to NTM may affect the efficacy of BCG vaccine. This finding has important implications as long as there is no replacement for the BCG vaccine on the horizon and as long as tuberculosis continues to kill 2-3 million people per year.


Related Articles

  • New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex. Collins, Dm; Collins, Desmond M // Immunology & Cell Biology;Aug2000, Vol. 78 Issue 4, p342 

    Summary The world urgently needs a better tuberculosis vaccine. Bacille Calmette–Guerin (BCG), an attenuated strain of Mycobacterium bovis, has been very widely used as a vaccine for many years but has had no major effect on reducing the incidence of tuberculosis. A number of alternative...

  • DEVELOPMENT OF AN ALTERNATIVE TB VACCINES USING CD40 CONJUGATION TECHNOLOGY. DeLeenheer, E.; Carlring, J.; Cookson, S.L.; Collin, M.; Huygen, K.; Heath, A.W. // Revista VacciMonitor (Vacunología y Temas Afines);2010 Supplement 1, Vol. 19, p11 

    Worldwide 2 billion people are infected with M. tuberculosis, many of which show no symptoms. However, 10% of latently infected patients progress to active disease, which poses a problem in developing countries with high HIV/AIDS prevalence. Until recently the BCG (Bacille Calmette-Guérin)...

  • Mycobacterium ulcerans disease. van der Werf, Tjip S.; Stinstra, Ymkje; Johnson, R. Christian; Phillips, Richard; Adjei, Ohene; Fleischer, Berhard; Wansbrough-Jones, Mark H.; Johnson, Paul D. R.; Portaels, Francoise; van der Graaf, WinetteT. A.; Asiedu, Kingsley // Bulletin of the World Health Organization;Oct2005, Vol. 83 Issue 10, p785 

    Mycobacterium ulcerans disease (Buruli ulcer) is an important health problem in several west African countries. It is prevalent in scattered foci around the world, predominantly in riverine areas with a humid, hot climate. We review the epidomiology, bacteriology, transmission, immunology,...

  • Vaccines: A souped-up version of BCG. Bell, Elaine // Nature Reviews Immunology;Oct2005, Vol. 5 Issue 10, p746 

    Discusses research being done on the increased protection against pulmonary tuberculosis from modified versions of the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine. Reference to the study by Leander Grode and colleagues published in a 2005 issue of the "Journal of Clinical...

  • Vaccination strategies for tuberculosis. Mehta, Abhinay; Tyagi, Rajeev K.; Goyal, Amit; Khatri, Kapil; Gupta, Prem N.; Vyas, S. P. // Current Science (00113891);12/10/2007, Vol. 93 Issue 11, p1501 

    The widespread plague of tuberculosis (TB) has continued despite the availability of licensed TB vaccine (BCG) and directly observed chemotherapy (DOTS) programmes. Also, emergence of multi-drug resistant strains of Mycobacterium tuberculosis presents serious challenges for the DOTS strategy....

  • `Poor' vaccine ruled out in TB puzzle. Day, Michael // New Scientist;7/13/96, Vol. 151 Issue 2038, p14 

    Reports on a British study designed to explain why the BCG vaccine often fails to protect against tuberculosis (TB) in developing countries. Rejection of notion that poor quality of vaccines render the TB treatment ineffective; Exposure of children in tropical countries to numerous other...

  • Improving vaccines against tuberculosis. Britton, Warwick J; Palendira, Umaimainthan // Immunology & Cell Biology;Feb2003, Vol. 81 Issue 1, p34 

    Summary Tuberculosis remains a major cause of mortality and physical and economic deprivation worldwide. There have been significant recent advances in our understanding of the Mycobacterium tuberculosis genome, mycobacterial genetics and the host determinants of protective immunity....

  • TB vaccine failure was predictable. Beverley, Peter // Nature;11/28/2013, Vol. 503 Issue 7477, p469 

    A letter to the editor is presented related to the role of the MVA85A vaccine, a tuberculosis (TB) vaccine, in the protection of TB over the Bacillus Calmette–Guérin (BCG) vaccine.

  • Editorial Response: Variation in Clinical and Immune Responses to Bacille Calmette-Guerin--Implications for an Improved Tuberculosis Vaccine.  // Clinical Infectious Diseases;4/1/1999, Vol. 28 Issue 4, p791 

    Comments on an article about the variation in clinical and immune responses to the tuberculosis vaccine bacille Calmette-Gu é rin. Concerns on the effectiveness of the vaccine; Observations on the duration of vaccine-induced ulceration; Need for further study to determine the limitations of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics